- Home
- DXR vs VRCA Comparison
DXR vs VRCA Comparison
Compare DXR & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- VRCA
- Stock Information
- Founded
- DXR 1970
- VRCA 2013
- Country
- DXR United States
- VRCA United States
- Employees
- DXR N/A
- VRCA N/A
- Industry
- DXR Medical/Dental Instruments
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- VRCA Health Care
- Exchange
- DXR Nasdaq
- VRCA Nasdaq
- Market Cap
- DXR 36.4M
- VRCA 43.0M
- IPO Year
- DXR N/A
- VRCA 2018
- Fundamental
- Price
- DXR $7.30
- VRCA $0.54
- Analyst Decision
- DXR Strong Buy
- VRCA Hold
- Analyst Count
- DXR 1
- VRCA 5
- Target Price
- DXR $25.00
- VRCA $6.00
- AVG Volume (30 Days)
- DXR 4.8K
- VRCA 246.4K
- Earning Date
- DXR 01-01-0001
- VRCA 05-13-2025
- Dividend Yield
- DXR N/A
- VRCA N/A
- EPS Growth
- DXR 86.16
- VRCA N/A
- EPS
- DXR 0.11
- VRCA N/A
- Revenue
- DXR $119,714.00
- VRCA $7,179,000.00
- Revenue This Year
- DXR N/A
- VRCA $127.58
- Revenue Next Year
- DXR N/A
- VRCA $88.06
- P/E Ratio
- DXR $66.24
- VRCA N/A
- Revenue Growth
- DXR N/A
- VRCA N/A
- 52 Week Low
- DXR $6.55
- VRCA $0.38
- 52 Week High
- DXR $10.00
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- DXR 44.11
- VRCA 57.01
- Support Level
- DXR $7.19
- VRCA $0.39
- Resistance Level
- DXR $7.74
- VRCA $0.48
- Average True Range (ATR)
- DXR 0.41
- VRCA 0.05
- MACD
- DXR -0.02
- VRCA 0.01
- Stochastic Oscillator
- DXR 27.40
- VRCA 90.75
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.